In the field of human biomonitoring (HBM), we offer a comprehensive range of LC-MS and GC-MS-based methods tailored for the precise quantitative determination of environmental chemicals and their specific metabolites in various biological matrices, including urine, serum, plasma and saliva. Our commitment to accuracy and precision is what sets us apart. Our methods are routinely used in biomonitoring campaigns, allowing us to comprehensively assess both occupational and non-occupational exposures to environmental chemicals. At the heart of our services is a commitment to improving understanding of how these substances interact with the human body, ultimately promoting a healthier and more sustainable future.

With over four decades of experience, ABF is a globally leading expert in bioanalysis for biomarkers of exposure related to tobacco and new emerging nicotine products, trusted by clients worldwide. We have analyzed biological samples for hundreds of (non-)clinical studies, applying the largest set of fully validated bioanalytical methods in the field of tobacco harm reduction. We continuously expand our portfolio by developing and validating bioanalytical methods for new biomarkers of exposure and biomarkers of potential harm, staying at the forefront of scientific advancements. At ABF, we are committed to help our clients responsibly launch new nicotine products in the marketplace. Choose ABF for reliable and cutting-edge bioanalysis services in the field of tobacco harm reduction.

At the forefront of scientific development, ABF is leading the way with innovative methods for the accurate analysis of cannabis and cannabinoids. Risk assessment of these new products using appropriate biomarkers is becoming increasingly important, particularly for pharmacokinetic (PK) and toxicokinetic (TK) studies, exposure assessment and risk evaluation. Our CBD and THC PK/TK assay runs according to GLP and GCP as part of our GLP-certified method portfolio. Our aim is to support you responsibly in the introduction of new products. ABF is your partner for reliable and innovative cannabinoid bioanalysis.

ABF is your trusted ISO17025 accredited and GLP certified research laboratory. We specialise in providing comprehensive bioanalytical services to the pharmaceutical and generic industries, offering unwavering support for drug development at all stages, including pharmacokinetic (PK), toxicokinetic (TK) and pharmacodynamic (PD) studies. Our expertise extends to the accurate identification of unknowns, including metabolites, impurities, degradation products, by-products and endogenous substances. We achieve this through the use of state-of-the-art high-resolution mass spectrometry platforms such as LC-Orbitrap-MS and GC-TOF-MS. Equipped with the latest bioanalytical technology, we ensure quality, accuracy and a remarkable turnaround time on every project. Our highly automated data processes streamline the analytical journey, making us your preferred choice for bioanalytical services.